Genomic Valley Biotech Ltd.
Genomic Valley Biotech Ltd. Fundamental Analysis
Genomic Valley Biotech Ltd. (GVBL.BO) shows weak financial fundamentals with a PE ratio of 72.52, profit margin of 18.62%, and ROE of 3.00%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 46.2/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze GVBL.BO's fundamental strength across five key dimensions:
Efficiency Score
WeakGVBL.BO struggles to generate sufficient returns from assets.
Valuation Score
ModerateGVBL.BO shows balanced valuation metrics.
Growth Score
WeakGVBL.BO faces weak or negative growth trends.
Financial Health Score
ModerateGVBL.BO shows balanced financial health with some risks.
Profitability Score
ModerateGVBL.BO maintains healthy but balanced margins.
Key Financial Metrics
Is GVBL.BO Expensive or Cheap?
P/E Ratio
GVBL.BO trades at 72.52 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, GVBL.BO's PEG of 0.73 indicates potential undervaluation.
Price to Book
The market values Genomic Valley Biotech Ltd. at 2.16 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 35.85 times EBITDA. This signals the market has high growth expectations.
How Well Does GVBL.BO Make Money?
Net Profit Margin
For every $100 in sales, Genomic Valley Biotech Ltd. keeps $18.62 as profit after all expenses.
Operating Margin
Core operations generate 32.75 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $3.00 in profit for every $100 of shareholder equity.
ROA
Genomic Valley Biotech Ltd. generates $0.00 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Genomic Valley Biotech Ltd. generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Genomic Valley Biotech Ltd. generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
GVBL.BO converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
72.52
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.73
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.16
vs 25 benchmark
P/S Ratio
Price to sales ratio
11.76
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.00
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.03
vs 25 benchmark
ROA
Return on assets percentage
0.00
vs 25 benchmark
ROCE
Return on capital employed
0.00
vs 25 benchmark
How GVBL.BO Stacks Against Its Sector Peers
| Metric | GVBL.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 72.52 | 28.45 | Worse (Expensive) |
| ROE | 3.00% | 763.00% | Weak |
| Net Margin | 18.62% | -45265.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 0.00 | 2795.60 | Weak Liquidity |
| ROA | 0.00% | -16588.00% (disorted) | Weak |
GVBL.BO outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Genomic Valley Biotech Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation